問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

更新時間：2023-09-19

林定佑
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

73Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林定佑

List

101Cases

2025-03-01 - 2028-03-31

Phase I/II

Active
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

  • Condition/Disease

    Non Small Cell Lung Carcinoma

  • Test Drug

    N/A

Participate Sites
8Sites

Recruiting8Sites

2025-12-01 - 2032-01-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

2022-12-01 - 2024-10-28

Phase II

Active
Phase 2, Open-Label Study in Subjects With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non Small Cell Lung Cancer

  • Test Drug

    Telisotuzumab vedotin (ABBV-399)

Participate Sites
4Sites

Recruiting4Sites

2020-09-20 - 2027-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2024-08-01 - 2029-09-06

Phase III

Active
A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1-selected non-small-cell lung cancer (GALAXIES LUNG-301)

  • Condition/Disease

    previously untreated, unresectable, locally advanced or metastatic PD-L1-selected non-small-cell lung cancer (GALAXIES LUNG-301)

  • Test Drug

    injection injection injection

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2020-04-01 - 2028-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-08-01 - 2024-11-01

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2022-05-01 - 2026-01-11

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2022-09-03 - 2027-08-09

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-05-01 - 2030-04-30

Phase III

Active
A Global, Multicenter, Randomized, Open?label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

  • Condition/Disease

    Extensive-stage small cell lung cancer (ES-SCLC)

  • Test Drug

    sacituzumab govitecan

Participate Sites
9Sites

Recruiting9Sites

1 2 3 4 5 6 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB